FDA OK’s Foamix topical acne foam

The FDA approves Foamix Pharmaceuticals’ (NASDAQ:FOMX) AMZEEQ (minocycline) topical foam, 4% (formerly FMX101) for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients at least nine years old.

Update: Shares, currently halted, will resume trading at 4:40 pm ET.

https://seekingalpha.com/news/3507048-fda-oks-foamix-topical-acne-foam